Show simple item record

dc.contributor.authorAnderson, Evan J
dc.contributor.authorKamidani, Satoshi
dc.contributor.authorOrenstein, Walt
dc.contributor.authorCampbell, James D
dc.date.accessioned2022-02-04T14:43:41Z
dc.date.available2022-02-04T14:43:41Z
dc.date.issued2022-01
dc.identifier.urihttp://hdl.handle.net/10713/17882
dc.description.abstractTO THE EDITOR—We agree that optimal drug doses in those ≥12 years of age have been similar to those identified for adults [1, 2]. Neither of our articles addressed the complexity of pediatric drug development [3, 4]. Importantly, the bar for vaccine licensure in healthy children is different from that for administration of a potentially lifesaving therapeutic. In addition, classic pharmacokinetic data (eg, clearance, volume of distribution) do not exist for locally administered vaccines. As such, we need to determine the vaccine dose and schedule from clinical trial data. While we can use “our present understanding of the developing human body” [2] as a starting point for rational clinical trials, we owe our children data on which to base vaccine licensure...en_US
dc.description.urihttps://doi.org/10.1093/cid/ciab400en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of Americaen_US
dc.titleReply to Rose et al.en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/ciab400
dc.identifier.pmid33949653
dc.source.journaltitleClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.source.volume74
dc.source.issue1
dc.source.beginpage169
dc.source.endpage170
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record